EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Mobile health technology integrated care in atrial fibrillation patients with diabetes mellitus in China: A subgroup analysis of the mAFA‐II cluster randomized clinical trial

Yutao Guo, Bernadette Corica iD, Giulio Francesco Romiti, Marco Proietti iD, Hui Zhang, Gregory Y H Lip, mAF-App II Trial Investigators

European Journal of Clinical Investigation · 2023

DOI: 10.1111/eci.14031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Clinical Investigation, 2023. Verfasst von Yutao Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Vessel and Thrombotic Disease, Medical School of Chinese PLA, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Diabetes Mellitus, Stroke, Telemedicine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA‐II) prospective randomized trial showed the efficacy of a mobile health (mHealth) implemented ‘Atrial fibrillation Better Care’ (ABC) pathway for the integrated care management of patients with atrial fibrillation (AF). In this ancillary analysis, we evaluated the effect of mAFA intervention according to the history of diabetes mellitus (DM).

Methods

The mAFA‐II trial enrolled 3324 AF patients across 40 centres in China, between June 2018 and August 2019. In this analysis, we assessed the interaction between history of DM and the effect of mAFA intervention on the risk of the primary composite outcome of stroke, thromboembolism, all‐cause death and rehospitalizations. Results were expressed as adjusted hazard ratio (aHR) and 95% confidence intervals (95%CI). The effect of mAFA intervention on exploratory secondary outcomes was also assessed.

Results

Overall, 747 (22.5%) patients had DM (mean age: 72.7 ± 12.3, 39.6% females; 381 allocated to mAFA intervention). mAFA intervention was associated with a significant risk reduction for the primary composite outcome both in patients with and without DM (aHR [95%CI]: .36 [.18–.73] and .37 [.23–.61], respectively, p for interaction = .941). A significant interaction was found only for the composite of recurrent AF, heart failure and acute coronary syndromes ( p int =.025), with lower effect of mAFA intervention in patients with DM.

Conclusions

A mHealth‐technology implemented ABC pathway showed a consistent effect in reducing the risk of the primary composite outcome in AF patients with and without DM. Trial Registration WHO International Clinical Trials Registry Platform (ICTRP) Registration number: ChiCTR‐OOC‐17014138.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDiabetes MellitusStrokeTelemedicineDelivery of Health Care, IntegratedFemaleHumansMaleProspective StudiesChinaAnticoagulants

Stichwörter der Autor:innen

atrial fibrillationdiabetes mellitusintegrated careoutcomes

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Pulmonary Vessel and Thrombotic Disease, Medical School of Chinese PLA, Chinese PLA General Hospital, Beijing, China.
  • Liverpool Centre for Cardiovascular Sciences at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
  • Department of Translational and Precision Medicine, Sapienza - University of Rome, Rome, Italy.
  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.
  • Danish Center for Clinical Health Services Research, Aalborg University, Aalborg, Denmark.

ORCID-Profile: Bernadette Corica, Marco Proietti

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, Y., Corica, B., Romiti, G. F., Proietti, M., Zhang, H., Lip, G. Y. H., & mAF-App II Trial Investigators (2023). Mobile health technology integrated care in atrial fibrillation patients with diabetes mellitus in China: A subgroup analysis of the mAFA‐II cluster randomized clinical trial. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14031

Vancouver

Guo Y, Corica B, Romiti GF, Proietti M, Zhang H, Lip GYH, et al. Mobile health technology integrated care in atrial fibrillation patients with diabetes mellitus in China: A subgroup analysis of the mAFA‐II cluster randomized clinical trial. European Journal of Clinical Investigation. 2023. doi:10.1111/eci.14031

BibTeX
@article{Guo2023,
  author = {Guo, Yutao and Corica, Bernadette and Romiti, Giulio Francesco and Proietti, Marco and Zhang, Hui and Lip, Gregory Y H and mAF-App II Trial Investigators, mAF-App II Trial Investigators},
  title = {Mobile health technology integrated care in atrial fibrillation patients with diabetes mellitus in China: A subgroup analysis of the mAFA‐II cluster randomized clinical trial},
  journal = {European Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1111/eci.14031}
}
Kostenlos starten →